A5002598170- Lung Cancer Treatments and Mutations
- Health Systems, Economic Evaluations, Quality of Life
- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Statistical Methods in Clinical Trials
- Statistical Methods and Inference
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- Innovation Policy and R&D
- Colorectal Cancer Treatments and Studies
- Pharmaceutical Economics and Policy
- Colorectal Cancer Screening and Detection
- Statistical Methods and Bayesian Inference
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
- Bladder and Urothelial Cancer Treatments
- Gastric Cancer Management and Outcomes
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
PAREXEL International (United Kingdom)
2022-2024
Immuno-oncology (IO) therapies are often associated with delayed responses that deep and durable, manifesting as long-term survival benefits in patients metastatic cancer. Complex hazard functions arising from IO treatments may limit the accuracy of extrapolations standard parametric models (SPMs). We evaluated ability flexible (FPMs) to improve using data 2 trials involving non-small-cell lung cancer (NSCLC).Our analyses used consecutive database locks (DBLs) at 2-, 3-, 5-y minimum...
528 Background: Durable DFS and cure are the ultimate goals for treatment of muscle invasive urothelial carcinoma (MIUC) with radical cystectomy. This analysis employed mixture models (MCMs) to estimate underlying fraction among high-risk MIUC patients following resection in Phase 3 CheckMate-274 study. Methods: MCMs were applied patient-level data from trial (minimum follow-up: 31.6 months). Intention-to-treat (ITT) population subpopulation tumor PD-L1 expression ≥1% analyzed separately...
Standard-of-care treatments for patients with resected stage III/IV melanoma include the immuno-oncology (IO) agents nivolumab (NIVO) and ipilimumab (IPI). This study used mixture cure models (MCMs) to estimate rates among treated NIVO or IPI in phase III CheckMate 238 (ClinicalTrials.gov identifier: NCT02388906) European Organization Research Treatment of Cancer (EORTC) 18071 NCT00636168) trials, assess impact use adjuvant immunotherapy on versus watchful waiting. MCMs were applied...